StudyFinder

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3) SMT112-3005

Status: Recruiting

The purpose of this study is to compare two treatment combinations for people with metastatic colorectal cancer who have not received treatment for cancer that has spread. Participants will receive chemotherapy with either ivonescimab or bevacizumab by IV. We want to learn how these treatment options compare. What we learn may help improve future treatment options for people with metastatic colorectal cancer.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• have colorectal cancer that has spread to other parts of the body
• have not previously received systemic treatment for metastatic colorectal cancer
• have at least one measurable tumor outside the brain
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• have a significant bowel obstruction
• have inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis
• have cancer that can currently be removed by surgery
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Cancer, Colon Cancer, Colorectal Cancer

Study Contact: Ajay Prakash - praka086@umn.edu
Principal Investigator: Ajay Prakash
Phase: PHASE3
IRB Number: STUDY00027628
See this study on ClinicalTrials.gov

Back